In some embodiments provided herein is a method of treating pain, the method comprising administering into the subject a pharmaceutical composition comprising multivesicular liposomes encapsulating bupivacaine phosphate, said multivesicular liposomes comprising bupivacaine or a salt thereof; phosphoric acid; a lipid component comprising at least one amphipathic lipid and at least one neutral lipid lacking a hydrophilic head group.

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

The embodiments disclose a method, including suspending cannabinoid compound molecules and constituents in an aqueous solution, suspending Aloe Vera molecules and its constituents in an aqueous solution, wherein a combination of cannabinoid compound molecules and constituents and Aloe Vera molecules and its constituents may be used for suspending in an aqueous solution, encapsulating cannabinoid compound molecules and Aloe Vera molecules within a liposome in an aqueous solution, and blending the liposome encapsulated cannabinoid compound molecules and Aloe Vera molecules with other ingredients into a health beneficial product and delivery system for oral including sublingual ingestion and nasal spray and suppository insertion or topical application with a plurality of nano sensors by humans.

The present invention discloses a nano-armored single cell product, comprising a liposome and probiotics encapsulated by the liposome, wherein the probiotics are fermented to produce gamma-aminobutyric acid (GABA) that alleviates the activation of an inflammatory response in substantia nigra inducedin a MPTP induced PD model, thus mitigating an inflammatory injury to dopaminergic neurons in substantia nigra and having a neuroprotective effect; encapsulation of the probiotics by the liposome can protect the probiotics from strong acids and digestive enzymes in gastric acid. The present invention uses the nano-armored single cell product for treating Parkinson's disease through bacteria and a preparation method thereof; with full use of the advantages of nano armor and bacterial treatment, the present invention decorates a single living cell with a nano armor coating, which can not only prevent toxic side effects caused by an excessive local GABA concentration, but also maintain GABA within a stable concentration range in the body, thus greatly improving the half-life period and neurological rehabilitation effect.

Dimer and monomer molecules according to general formulas (I) or (II) are useful as lipid switch molecules when incorporated into a membrane of a liposome.

##STR00001##

wherein R.sup.1 is a hydrophobic tail having at least 6 carbons and wherein R.sup.2 is selected from the group consisting of —NH.sub.2,

##STR00002##

wherein, for the dimer, the linker is a saturated carbon chain having 2 to 6 carbons or is a para-xylene linker; and when R.sup.2 is charged anions are present to render the charge neutral. These molecules can bind ATP or similar small phosphorylated molecules between R.sup.2 groups, which changes the shape of the molecule or the molecules orientation within the membrane thereby acting as a “switch” to release a therapeutic agent from the liposome.

The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

An object is to achieve a nanostructure that has structural stability and temperature responsivity. Provided is a nanostructure which is a hollow body constituted by a wall, the wall including a first region and a second region, the first region being formed from an assembly of a plurality of first amphiphilic molecules containing a hydrophilic block and a hydrophobic block, the second region being formed from an assembly of a plurality of second amphiphilic molecules which are different from the first amphiphilic molecules, the first region being arranged to be in its solid phase at a phase transition temperature at which the second region of the wall transitions from its solid phase to its liquid phase.

Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

A method for chemically induced homing of extracellular vesicles (EVs) to a specific tissue or organ in a subject for either treatment or diagnosis of a medical condition, the method comprising administering to the subject an amount of a homing agent. The homing agent is at least one of a derivative of polyethylene glycol), or a derivative of phenothiazine;. The EVs are homed to the homing agent in the subject.